A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

Running, not enrolling · Phase 1/Phase 2

Conditions studied: Sickle Cell Disease, Hemoglobinopathies

In brief

The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult and adolescent participants with severe sickle cell disease (SCD).

Key facts

Study ID
NCT04853576
Run by
Editas Medicine, Inc.
People needed
45
Starts
2021-05-04
Expected to finish
2025-08-01
Last updated by the study team
2025-01-31

Who can join

Age: 12 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.